HIV/AIDS
Conditions
Interventions
Sponsors
USM
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Adults =18 years with confirmed HIV, • HIV-positive individuals aged 18 years and older. • Primary use of English or Arabic for oral and written communication. • =3 comorbid conditions associated with increased healthcare utilization (e.g., CHF, DM, COPD, HTN, opportunistic infections). • =2 visits to a physician or advanced practice provider at the study site clinic over the past year. • =8 chronic prescription medications over the 6 months prior to study enrollment. • Have a telephone line available for at least 6 months. • Willingness to participate in the study and provide informed consent. • Situation placing the patient at risk for a drug-related problem (DRP): Change in medication, new physician visit, ER visit, hospitalization, invasive procedure within the last 30 days, or seeing 3 or more providers within 12 months.
Exclusion criteria
Exclusion criteria: • Terminal condition with life expectancy =6 months • Previous enrolment in the MTM program with medication reconciliation or assessment for DRPs within 12 months. • Inability to provide informed consent or participate in the study due to cognitive impairment or other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Medication Adherence Description: Medication adherence to antiretroviral therapy measured by Proportion of Days Covered (PDC) from pharmacy refill records. PDC = (Number of days with medication available) / (Number of days in measurement period) × 100. High adherence defined as PDC = 95%. Metric/Method of MeasurementProportion of Days Covered (PDC) calculated from pharmacy refill records | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Viral Load Suppression Proportion of participants with HIV RNA <200 copies/mL;2. CD4 Count Change Mean change in CD4+ T-lymphocyte count from baseline;3. Drug-Related Problems Number and types identified and resolved (PCNE classification);4. Adverse Drug Events Incidence and severity using Naranjo criteria;5. Healthcare Utilization Number of hospitalizations, emergency visits, unscheduled clinic visits;6. Health-Related Quality of Life EQ-5D-5L instrument score;7. Patient Satisfaction Pharmaceutical care satisfaction questionnaire score;8. Medication Knowledge Validated medication knowledge questionnaire ;9. Self-Efficacy HIV Treatment Adherence Self-Efficacy Scale (HIV-ASES);10. Cost-Effectiveness Incremental cost per QALY gained | — |
Countries
Sudan
Contacts
Public ContactHasni bin Arsad
Deputy Director Research and Networking Advanced Medical and Dental Institute Universiti Sains Malaysia
Outcome results
None listed